Animalcare Group Plc engages in the development, sale, and supply of generic veterinary medicines and animal identification products. The company is headquartered in York, North Yorkshire and currently employs 201 full-time employees. The company went IPO on 2008-01-15. The company is focused on bringing products to market through its own development pipeline, partnerships and through acquisitions. Its principal activity is the development, sale and distribution of licensed veterinary pharmaceuticals to the Companion Animal, Production Animal and Equine veterinary markets. The company develops and commercializes prescription and over-the-counter pharmaceutical products that improve animal health and wellbeing. The company manages an international supply chain, including specialist veterinary wholesalers and distributors. Its novel products include Plaqtiv+ and Daxocox. Daxocox is a long-acting stand for the treatment of osteoarthritic pain. Plaqtiv+ is a dental homecare solution for dogs and cats. The firm also oversees the VHH NGF program, which is dedicated to researching the effectiveness of antibodies in the treatment of pain caused by osteoarthritis in horses and dogs.